Form 4: Teva Pharmaceutical Director Reports Vesting of RSUs and New Grant

Gerald M. Lieberman, a Director at Teva Pharmaceutical Industries Ltd., reported the vesting of 9,632 restricted share units and the grant of an additional 14,492 restricted share units.

Summary

• Gerald M. Lieberman, a Director of Teva Pharmaceutical Industries Ltd. (TEVA), filed a Form 4 reporting changes in his beneficial ownership.
• On June 6, 2025, 9,632 Restricted Share Units (RSUs) that were granted on June 6, 2024, vested and were converted into 9,632 Ordinary Shares of Teva.
• Additionally, on June 5, 2025, Mr. Lieberman was granted 14,492 new Restricted Share Units, which are scheduled to vest on June 5, 2026.
• Each RSU represents a contingent right to receive one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
• Following these transactions, Mr. Lieberman directly beneficially owns 115,657 Ordinary Shares and 14,492 Restricted Share Units.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects a director's continued equity participation and compensation, which aligns their interests with shareholders. However, it's a routine compensation event and not indicative of significant operational or financial news.

Positives

• The vesting of RSUs and the grant of new RSUs indicate ongoing compensation and retention of a key director.
• The director's continued accumulation of shares (through RSU vesting) aligns his interests with shareholders.

Future Outlook

The document primarily details past and scheduled insider transactions related to compensation, and does not provide forward-looking statements regarding the company's financial performance or strategic outlook beyond the vesting schedule of the newly granted RSUs.

Industry Context

This Form 4 filing is a routine disclosure of insider compensation and does not provide specific insights into broader pharmaceutical industry trends or Teva's competitive positioning. Such filings are standard for publicly traded companies to ensure transparency regarding executive and director equity holdings.

Stakeholder Impact

• Shareholders: The transactions demonstrate a director's continued equity interest in the company, potentially aligning their long-term interests with those of shareholders.
• Employees: The RSU grant is part of executive compensation, which is a standard practice in corporate remuneration.

Next Steps

• The 14,492 Restricted Share Units granted on June 5, 2025, are expected to vest on June 5, 2026.

Key Dates

Recommendation

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Trading, Restricted Share Units, RSU, Stock Grant, Director Compensation, Beneficial Ownership, SEC Filing